ABBV
Price
$220.78
Change
+$4.52 (+2.09%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
382.04B
37 days until earnings call
PFE
Price
$24.04
Change
+$0.14 (+0.59%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
135.88B
48 days until earnings call
Interact to see
Advertisement

ABBV vs PFE

Header iconABBV vs PFE Comparison
Open Charts ABBV vs PFEBanner chart's image
ABBVIE
Price$220.78
Change+$4.52 (+2.09%)
Volume$56.68K
Capitalization382.04B
Pfizer
Price$24.04
Change+$0.14 (+0.59%)
Volume$204.9K
Capitalization135.88B
ABBV vs PFE Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. PFE commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and PFE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (ABBV: $216.26 vs. PFE: $23.90)
Brand notoriety: ABBV and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 90% vs. PFE: 133%
Market capitalization -- ABBV: $382.04B vs. PFE: $135.88B
ABBV [@Pharmaceuticals: Major] is valued at $382.04B. PFE’s [@Pharmaceuticals: Major] market capitalization is $135.88B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $685.53B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, ABBV is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).

  • ABBV’s TA Score: 4 bullish, 4 bearish.
  • PFE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than PFE.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а +2.78% price change this week, while PFE (@Pharmaceuticals: Major) price change was -3.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.05%. For the same industry, the average monthly price growth was +0.38%, and the average quarterly price growth was +11.67%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

PFE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.05% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($382B) has a higher market cap than PFE($136B). ABBV has higher P/E ratio than PFE: ABBV (102.98) vs PFE (12.65). ABBV YTD gains are higher at: 25.053 vs. PFE (-5.067). PFE has higher annual earnings (EBITDA): 20.2B vs. ABBV (14.2B). PFE has more cash in the bank: 13.2B vs. ABBV (6.47B). PFE has less debt than ABBV: PFE (60.9B) vs ABBV (70.5B). PFE has higher revenues than ABBV: PFE (63.8B) vs ABBV (58.3B).
ABBVPFEABBV / PFE
Capitalization382B136B281%
EBITDA14.2B20.2B70%
Gain YTD25.053-5.067-494%
P/E Ratio102.9812.65814%
Revenue58.3B63.8B91%
Total Cash6.47B13.2B49%
Total Debt70.5B60.9B116%
FUNDAMENTALS RATINGS
ABBV vs PFE: Fundamental Ratings
ABBV
PFE
OUTLOOK RATING
1..100
6872
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
9100
SMR RATING
1..100
1362
PRICE GROWTH RATING
1..100
2961
P/E GROWTH RATING
1..100
1498
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (88). This means that PFE’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that ABBV’s stock grew significantly faster than PFE’s over the last 12 months.

ABBV's SMR Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (62). This means that ABBV’s stock grew somewhat faster than PFE’s over the last 12 months.

ABBV's Price Growth Rating (29) in the Pharmaceuticals Major industry is in the same range as PFE (61). This means that ABBV’s stock grew similarly to PFE’s over the last 12 months.

ABBV's P/E Growth Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (98). This means that ABBV’s stock grew significantly faster than PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVPFE
RSI
ODDS (%)
Bearish Trend 2 days ago
42%
Bearish Trend 2 days ago
53%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
46%
Bullish Trend 2 days ago
56%
Momentum
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
65%
MACD
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
50%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
58%
Advances
ODDS (%)
Bullish Trend 7 days ago
57%
Bullish Trend 16 days ago
57%
Declines
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 14 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
33%
Bullish Trend 2 days ago
52%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
52%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ABXB19.950.12
+0.60%
Abacus Flexible Bond Leaders ETF
FYT56.560.08
+0.13%
First Trust Small Cap Val AlphaDEX® ETF
VGM9.99N/A
+0.05%
Invesco Trust Investment Grade Municipals
MEXX22.45-0.03
-0.13%
Direxion Dly MSCI Mexico Bull 3X ShsETF
PAVE46.48-0.26
-0.56%
Global X US Infrastructure Dev ETF